Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 182-189

  Fukamachi, Toshihiko ^a   Chiba, Yoshie ^a   Wang, Xin ^a   Saito, Hiromi ^a   Tagawa, Masatoshi ^b   Kobayashi, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Acidic pH; Anti cancer reagents; Cantharidin; Lovastatin; Mesothelioma; Pancreatic carcinoma

Indexed keywords

APHIDICOLIN; CANTHARIDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MANUMYCIN; MEVINOLIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARCINOMA CELL; CELL COUNT; CELL PH; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MESOTHELIOMA; PANCREAS CARCINOMA; PRENYLATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; CELL GROWTH; DOSE RESPONSE; DRUG EFFECTS; HELA CELL LINE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PH; TUMOR CELL LINE;

CANTHARIDIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MESOTHELIOMA; PANCREATIC NEOPLASMS;

EID: 77956474732     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.010     Document Type: Article

References (41)

1. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res. 1989, 49:6449-6465.
2. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3:177-182.
3. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
4. Vukovic V., Tannock I.F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 1997, 75:1167-1172.
5. Sauvant C., Nowak M., Wirth C., Schneider B., Riemann A., Gekle M., Thews O. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int. J. Cancer 2008, 123:2532-2542.
6. Fukamachi T., Saito H., Kakegawa T., Kobayashi H. Different proteins are phosphorylated under acidic environments in Jurkat cells. Immunol. Lett. 2002, 82:155-158.
7. Hirata S., Fukamachi T., Sakano H., Tarora A., Saito H., Kobayashi H. Extracellular acidic environments induce phosphorylation of ZAP-70 in Jurkat T cells. Immunol. Lett. 2008, 115:105-109.
8. Lao Q., Fukamachi T., Saito H., Kuge O., Nishijima M., Kobayashi H. Requirement of an IkappaB-beta COOH terminal region protein for acidic-adaptation in CHO cells. J. Cell Physiol. 2006, 207:238-243.
9. Fukamachi T., Lao Q., Okamura S., Saito H., Kobayashi H. CTIB (C-terminus protein of IkappaB-beta): a novel factor required for acidic adaptation. Adv. Exp. Med. Biol. 2006, 584:219-228.
10. Zucali P.A., Giaccone G. Biology and management of malignant pleural mesothelioma. Eur. J. Cancer 2006, 42:2706-2714.
11. Catalano A., Rodilossi S., Rippo M.R., Caprari P., Procopio A. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J. Biol. Chem. 2004, 279:46706-46714.
12. Pierantoni C., Pagliacci A., Scartozzi M., Berardi R., Bianconi M., Cascinu S. Pancreatic cancer: progress in cancer therapy. Crit. Rev. Oncol. Hematol. 2008, 67:27-38.
13. Hochster H.S., Haller D.G., de Gramont A., Berlin J.D., Philip P.A., Moore M.J., Ajani J.A. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006, 107:676-685.
14. Louvet C., Labianca R., Hammel P., Lledo G., G Zampino M., André T., Zaniboni A., Ducreux M., Aitini E., Taïeb J., Faroux R., Lepere C., de Gramont A. GERCOR; GISCAD, gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005, 23:3509-3516.
15. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., Lippman S.M. Statins and cancer prevention. Nat. Rev. Cancer 2005, 5:930-942.
16. Gbelcová H., Lenícek M., Zelenka J., Knejzlík Z., Dvoráková G., Zadinová M., Poucková P., Kudla M., Balaz P., Ruml T., Vítek L. Differences in antitumor effects of various statins on human pancreatic cancer. Int. J. Cancer 2008, 122:1214-1221.
17. Riganti C., Orecchia S., Silvagno F., Pescarmona G., Betta P.G., Gazzano E., Aldieri E., Ghigo D., Bosia A. Asbestos induces nitric oxide synthesis in mesothelioma cells via Rho signaling inhibition. Am. J. Resp. Cell Mol. Biol. 2007, 36:746-756.
18. Rubins J.B., Greatens T., Kratzke R.A., Tan A.T., Polunovsky V.A., Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Resp. Crit. Care Med. 1998, 157(5 Pt. 1):1616-1622.
19. Riganti C., Orecchia S., Pescarmona G., Betta P.G., Ghigo D., Bosia A. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int. J. Cancer 2006, 119:17-27.
20. Jani J.P., Specht S., Stemmler N., Blanock K., Singh S.V., Gupta V., Katoh A. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invas. Metast. 1993, 13:314-324.
21. Hawk M.A., Cesen K.T., Siglin J.C., Stoner G.D., Ruch R.J. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett. 1996, 109:217-222.
22. Zorbas-Seifried S., Hartinger C.G., Meelich K., Galanski M., Keppler B.K., Zorbas H. DNA interactions of pH-sensitive, antitumor bis(aminoalcohol)dichloroplatinum(II) complexes. Biochemistry 2006, 45:14817-14825.
23. Joshi H.N., Fakes M.G., Serajuddin A.T.M. Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity. Pharm. Pharm. Commun. 1999, 5:269-271.
24. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation 1998, 98:839-844.
25. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendörfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. Relation between baseline and ontreatment lipid parameters and first acute major coronary events in the air force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.
26. Wong W.W., Dimitroulakos J., Minden M.D., Penn L.Z. HMB-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16:508-519.
27. Fuchs D., Berges C., Opelz G., Daniel V., Naujokat C. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem. Biophys. Res. Commun. 2008, 374:309-314.
28. Montero J., Morales A., Llacuna L., Lluis J.M., Terrones O., Basañez G., Antonsson B., Prieto J., García-Ruiz C., Colell A., Fernández-Checa J.C. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008, 68:5246-5256.
29. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 2001, 7:687-692.
30. Hyvelin J.M., O'Connor C., McLoughlin P. Effect of changes in pH on wall tension in isolated rat pulmonary artery: role of the RhoA/Rho-kinase pathway. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287:L673-684.
31. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M., Smulson M.E., Yamin T.-T., Yu V.L., Miller D.K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43.
32. Oliver F.J., de la Rubia G., Rolli V., Ruiz-Ruiz M.C., de Murcia G., Murcia J.M. Murcia, Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J. Biol. Chem. 1998, 273:33533-33539.
33. Kok S.H., Cheng S.J., Hong C.Y., Lee J.J., Lin S.K., Kuo Y.S., Chiang C.P., Kuo M.Y. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett. 2005, 217:43-52.
34. Sagawa M., Nakazato T., Uchida H., Ikeda Y., Kizaki M. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway. Cancer Sci. 2008, 99:1820-1826.
35. Rauh R., Kahl S., Boechzelt H., Bauer R., Kaina B., Efferth T. Molecular biology of cantharidin in cancer cells. Chin. Med. 2007, 2:8.
36. Inselburg J., Banyal H.S. Plasmodium falciparum: synchronization of asexual development with aphidicolin, a DNA synthesis inhibitor. Exp. Parasitol. 1984, 57:48-54.
37. Kumagai M., Makioka A., Ohtomo H., Kobayashi S., Takeuchi T. Entamoeba invadens: reversible effects of aphidicolin on the growth and encystations. Exp. Parasitol. 1998, 90:294-297.
38. Liu P.K., Chang C.C., Trosko J.E., Dube D.K., Martin G.M., Loeb L.A. Mammalian mutator mutant with an aphidicolin-resistant DNA polymerase alpha. Proc. Natl. Acad. Sci. USA 1983, 80:797-801.
39. Syljuåsen R.G. Checkpoint adaptation in human cells. Oncogene 2007, 26:5833-5839.
40. Herbst R.S., Kies M.S. Gefitinib: current and future status in cancer therapy. Clin. Adv. Hematol. Oncol. 2003, 1:466-472.
41. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Láng I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Rüschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Herceptin adjuvant (HERA) trial study team, trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.